Chile looks at non-AUGE coverage:
This article was originally published in Clinica
Chile has expressed general satisfaction at the results of an assessment of the quality of primary and secondary care services not covered by the AUGE "explicit healthcare guarantees" programme, but acknowledges that some areas will need improving. Low rates of cervical smear (Pap) screening and apparent deficiencies in the care of diabetes and hypertension are a source of concern, said the government's subsecretary of healthcare networks, Ricardo Fabrega. In addition, progress in providing hip replacement surgery (in age groups exempt from AUGE) had "slightly levelled out", he said. Despite this, "the results of this study refute suggestions that Plan AUGE would result in deficiencies in areas of care that are not yet included in the programme," said Mr Fabrega.
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.